BioAegis Therapeutics Announces Publication in the Journal of Infectious Diseases: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Sensitive and Resistant Pneumococcal Pneumonia"
August 22, 2019 10:15 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 22, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing technology to control inflammation while protecting immune function and vital...
BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients
August 07, 2019 10:00 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring...
Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease
July 23, 2019 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
March 18, 2019 11:00 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN)...
BioAegis Therapeutics Expands Phase 1b/2a Community-Acquired Pneumonia Study to the Republic of Georgia —Successfully Completes Second of Four Dosing Cohorts
February 07, 2019 09:17 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that patient enrollment is underway in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...
BioAegis Therapeutics and the T.H. Chan-Harvard School of Public Health Demonstrate “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” at ID Week
October 18, 2017 13:33 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J. and BOSTON, Oct. 18, 2017 (GLOBE NEWSWIRE) -- (BIOAEGIS THERAPEUTICS)BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN)...
BioAegis Therapeutics Hires Dr. Mark J. DiNubile as Chief Medical Officer to Spearhead Forthcoming Phase 2 Clinical Trials in Community-Acquired Pneumonia
October 13, 2017 10:00 ET
|
BioAegis Therapeutics
BOSTON and MORRISTOWN, N.J., Oct. 13, 2017 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN) in augmenting innate...
Customer loyalty scores for biologic API contract manufacturers slip
February 08, 2017 11:00 ET
|
Industry Standard Research
CARY, NC--(Marketwired - February 08, 2017) - The 2nd edition of Industry Standard Research's (ISR's) Biologic API Contract Manufacturer Quality Benchmarking report indicates that buyers of...
Sponsors Anticipate Considerable Growth in Outsourced Bioprocessing Over the Next Five Years
April 26, 2016 10:30 ET
|
Industry Standard Research
CARY, NC--(Marketwired - April 26, 2016) - A new report titled Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021, from Industry Standard Research (ISR), indicates considerable...
Global Biologic Drugs Market to Jump to Over $220 Billion by 2019 says Latest Report
September 24, 2013 10:43 ET
|
Research and Markets
Dublin, Sept. 24, 2013 (GLOBE NEWSWIRE) -- Research and Markets
(http://www.researchandmarkets.com/research/2lg99t/biologics_and)
has announced the addition of the "Biologics
and...